Cape Investment Advisory, Inc.
Position in NBIX — Neurocrine Biosciences Inc
CIK 1944437
MCDONOUGH, GA
Position in NBIX
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$6,067
+$1,103 QoQ
Shares Held
36
+2.9% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#700
of 768 holders
Holding Since
Dec 2023
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Cape Investment Advisory, Inc. holds $246,280 across 9 Drug Manufacturers - Specialty & Generic names. NBIX ranks #5 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TEVA |
Teva Pharmaceutical Industries Ltd
|
3,133 | $106,145 | |
| 2 | ZTS |
Zoetis Inc.
|
1,138 | $81,775 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
66 | $35,760 | |
| 4 | HIMS |
Hims & Hers Health, Inc.
|
200 | $6,934 | |
| 5 | NBIX |
Neurocrine Biosciences Inc
This page
|
36 | $6,067 | |
| 6 | HLN |
Haleon plc
|
650 | $6,064 | |
| 7 | VTRS |
Viatris Inc
|
221 | $3,509 | |
| 8 | CGC |
Canopy Growth Corp
|
23 | $21 |
All Filings in NBIX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,067 | 36 | Shares | Defined | 2026-07-23 | |
| 2025-12-31 | $4,964 | 35 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $4,913 | 35 | Shares | Defined | 2025-12-29 | |
| 2025-06-30 | $4,399 | 35 | Shares | Defined | 2025-08-19 | |
| 2023-12-31 | $2,635 | 20 | Shares | Sole | 2024-02-12 | |
| No filing history on record for this holder in this stock. | ||||||